Press Releases
July 1, 2009
Discovery Labs Reports on Surfaxin End of Review Meeting with FDA
May 13, 2009
Discovery Labs Announces Completion of $11.3 Million Registered Direct Offering
May 11, 2009
Discovery Labs and FDA to Meet on June 2, 2009 to Discuss SURFAXIN Complete Response Letter
May 08, 2009
Discovery Labs to Raise $11.3 Million in Registered Direct Offering
May 05, 2009
Discovery Labs’ Surfaxin® Significantly Improves Lung Surfactant Distribution in Preclinical RDS Model
May 04, 2009
Discovery Labs’ KL4 Surfactant Shows Physiologic and Survival Benefit in a Preclinical Model for Severe Respiratory Condition – Acute Lung Injury
May 01, 2009
Discovery Labs Receives Notice of Allowance for Patent to Treat Infants at Risk of Developing Bronchopulmonary Dysplasia
April 28, 2009
Discovery Labs Reports First Quarter 2009 Financial Results
April 27, 2009
Discovery Labs Presents Pharmacoeconomic Data Linking Decreased Hospital Costs to Reduction in Reintubation Following Surfaxin Use
April 20, 2009
Discovery Labs Receives Complete Response from FDA
for Surfaxin® for Prevention of RDS
April 14, 2009
Discovery Labs Provides Update Regarding Surfactant Aerosol Generation Technology
March 30, 2009
Discovery Labs to Highlight Respiratory Pipeline at the Future Leaders in the Biotech Industry Conference
March 26, 2009
Discovery Labs Advances KL4 Surfactant Technology Platform with Lyophilized Formulation
March 13, 2009
Discovery Labs Reports Fourth Quarter 2008 Financial Results
January 5, 2009
Discovery Labs’ Surfaxin® Phase 2 BPD Clinical Trial Results
Published in Pediatrics
December 18, 2008
New Analysis of Discovery Labs’ Phase 3 RDS Trials Identifies
Reintubation as Key Risk Factor for Infant Mortality
December 15, 2008
Discovery Labs Secures $25 Million Committed Equity Financing Facility
November 13, 2008
Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference
November 7, 2008
FDA Establishes Target Action Date of April 17, 2009 for Potential Approval of Discovery Labs’ Surfaxin®
November 4, 2008
Discovery Labs reports that it has not yet received FDA Notification regarding Complete Response
November 4, 2008
Discovery Labs Reports Third Quarter 2008 Financial Results
October 29, 2008
Discovery Labs KL-4 Surfactant Data Presented at Two Key Medical Meetings
October 17, 2008
Discovery Labs Submits Complete Response to May 2008 FDA Approvable Letter for Surfaxin for RDS
September 24, 2008
Discovery Labs Reports Technical Achievements Towards Gaining FDA Approval of Surfaxin
September 3, 2008
Discovery Labs’ Aerosolized KL-4 Surfactant Selected for Evaluation in Phase 2a Cystic Fibrosis Clinical Trial
August 6, 2008
Discovery Labs Reports Progress in Responding to Surfaxin FDA Approvable Letter
August 6, 2008
Discovery Labs Reports Second Quarter 2008 Financial Results
July 30, 2008
Discovery Labs Announces Second Quarter Conference Call and Webcast
July 29, 2008
Discovery Labs KL-4 Surfactant Anti-Inflammatory Data Published in Pediatric Research
June 19, 2008
Discovery Labs and FDA Meet to Clarify Limited Items in SURFAXIN Approvable Letter
May 29, 2008
Discovery Labs and FDA to Meet on June 18, 2008 to Clarify Limited Items in SURFAXIN Approvable Letter
May 27, 2008
Discovery Labs Secures $60 Million Committed Equity Financing Facility
May 13, 2008
Securities Class Action Against Discovery Labs is Dismissed
May 7, 2008
Discovery Labs KL-4 Surfactant Technology Displays Antimicrobial Properties and Does Not Induce Immune Response in Preclinical Models
May 7, 2008
Discovery Labs Presents Surfaxin® Data at Pediatric Academic Societies
Annual Meeting
May 6, 2008
Discovery Labs Reports First Quarter 2008 Financial Results
May 5, 2008
Discovery Labs Provides Guidance on FDA Approvable Letter for Surfaxin® for RDS
May 2, 2008
Discovery Labs Receives an Approvable Letter from FDA for Surfaxin® for RDS
April 2, 2008
Discovery Labs and Chrysalis Technologies Modify Collaboration for Future
Development of Aerosolized Drug Device Products
March 27, 2008
Discovery Labs Adds Two Executives to Its Management Team
February 14, 2008
Discovery Labs Reports Fourth Quarter 2007 Financial Results
February 7, 2008
Discovery Labs Announces Fourth Quarter Conference Call and Webcast
December 13, 2007
Discovery Labs Announces Completion of $25 Million Registered Direct Offering
December 7, 2007
Discovery Labs to Raise $25 Million in Registered Direct Offering
December 3, 2007
Discovery Labs’ Aerosurf™ Improves Lung Function and Reduces Inflammation in a Model of Respiratory Distress Syndrome
November 16, 2007
Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference
November 16, 2007
Discovery Labs’ Response to Surfaxin® Approvable Letter Deemed Complete by FDA
November 1, 2007
Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin® for RDS in Premature Infants
October 30, 2007
Discovery Labs Announces Third Quarter Conference Call and Webcast
October 1, 2007
Surfaxin® Process Validation Batches Achieve Stability Milestone to Enable Filing of Response to FDA Approvable Letter
August 2, 2007
Discovery Labs Provides Update on Progress for Surfaxin® for RDS
August 2, 2007
Discovery Labs Reports Second Quarter 2007 Financial Results
July 25, 2007
Discovery Labs Announces Second Quarter Conference Call and Webcast
June 13, 2007
Discovery Labs to Present at the Jefferies Health Care Conference
June 7, 2007
Discovery Labs Initiates Phase 2 Clinical Trial in Children with Acute Respiratory Failure
May 31, 2007
Surfaxin® (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
May 9, 2007
Discovery’s KL-4 Surfactant Technology Demonstrates Novel Anti-inflammatory Properties
May 8, 2007
Discovery Labs Presents Surfaxin® and Aerosurf™ Data at the Pediatric Academic Societies Annual Meeting
May 2, 2007
Discovery Labs Reports First Quarter 2007 Financial Results
April 26, 2007
Discovery Labs Announces First Quarter Conference Call and Webcast
April 06, 2007
Discovery Labs Announces Completion of $30 Million Registered Direct Offering
April, 03 2007
Discovery Labs to Raise $30 Million in Registered Direct Offering
March, 20 2007
Discovery Labs Announces Federal Court’s Dismissal of Class Action Law Suits
March, 14 2007
W. Thomas Amick appointed Chairman of Discovery Labs’ Board of Directors
March 6, 2007
Discovery Labs to Present at the Cowen & Company Health Care Conference
February, 28 2007
Discovery Labs Reports Fourth Quarter 2006 Financial Results
February 27, 2006
Discovery Labs Announces Fourth Quarter Conference Call and Webcast
Januaury, 22 2007
Discovery Labs and FDA Reach Clarity on Path Towards Surfaxin® RDS Approval
December 1, 2006
Discovery Labs to Present at the BMO Capital Markets Conference
November 22, 2006
Discovery Labs Completes $10.0 Million Private Financing
November 16, 2006
Discovery Labs to Present at the Lazard Life Sciences Conference
November 8, 2006
Discovery Labs Reports Third Quarter 2006 Financial Results
November 6, 2006
Discovery Labs Announces Federal Court’s Dismissal of
Class Action Law Suits
November 3, 2006
Discovery Labs Announces Third Quarter Conference Call and Webcast
October 26, 2006
Discovery Labs Restructures Loan Arrangement with Quintiles
October 11, 2006
Discovery Labs Announces Topline Results of Surfaxin Phase 2 Clinical Trial
for the Prevention and Treatment of BPD
October 10, 2006
Surfaxin® Treated Premature infants Require Fewer Re-intubations Compared with Animal Derived Surfactants
September 28, 2006
Discovery Labs Updates Progress on Manufacturing Remediation
and Surfaxin® FDA Regulatory Matters
July 28, 2006
Discovery Labs Reports Second Quarter
2006 Financial Results
July 26, 2006
Discovery Labs Announces Second Quarter
Conference Call and Webcast
June 27, 2006
Discovery Labs Reports Progress on its Surfactant
Manufacturing Remediation
June 21, 2006
Pulmonary Surfactant Commercial Expert Rejoins
Discovery Labs’ Executive Management Team
June 20, 2006
Discovery Labs Retains Jefferies & Company to Assist in the
Evaluation of Potential Strategic Alternatives
June 19, 2006
Discovery Labs to Present at the Jefferies Life
Sciences Conference
June 15, 2006
Discovery Labs’ Surfaxin® Granted Orphan Drug
Designation for the Prevention of Bronchopulmonary
Dysplasia
June 7, 2006
Discovery Labs Withdraws European Marketing
Application for Surfaxin®
May 10, 2006
Discovery Labs Reports First Quarter 2006
Financial Results
May 10, 2006
Discovery Labs Announces First Quarter Conference Call
and Webcast
May 5, 2006
Discovery Labs Announces Corporate Reorganization and
Personnel Reduction
April 24, 2006
Discovery Labs
Reports Surfaxin Manufacturing Issue
April 20, 2006
Discovery Labs
Provides Business and Financial Update
April 19, 2006
Discovery Labs
Secures $50 Million Committed Equity Financing Facility
April 12, 2006
Discovery Labs Provides Update on Surfaxin Regulatory
Progress
April 5, 2006
Discovery Labs
Receives Second Approvable Letter from FDA for Surfaxin
for RDS
March 30, 2006
Discovery Labs
Announces Preliminary Results of Phase 2 Clinical Trial
in ARDS
March 2, 2006
Discovery Labs to Present at the SG Cowen & Co. 26th
Annual Health Care Conference
February 24, 2006
Discovery Labs Grants 10 Neonatology Fellowship
Awards
February 23, 2006
Discovery Labs
Reports Fourth Quarter 2005 Financial Results and
Business Progress
February 17, 2006
Discovery Labs
Announces Fourth Quarter Conference Call and Webcast
February 10, 2006
Discovery Labs
to Present at the BIO CEO & Investor Conference
February 6, 2006
Discovery Labs Adds Senior Medical and Clinical
Executives with Broad Pulmonology Expertise
February 1, 2006
Discovery Labs to Present at the Brean Murray, Carret &
Company Annual Institutional Investor Conference
January
26, 2006
FDA Grants Discovery Labs’ Surfaxin® Fast Track
Designation for Prevention and Treatment of
Bronchopulmonary Dysplasia
January 12, 2006
Discovery Labs to Present at the JP Morgan Healthcare
Conference
2005
December 28, 2005
Discovery Labs’ Broadens Management Team - Hires Senior
Manufacturing and Quality Executives
December 28, 2005
Discovery Labs to Acquire Laureate Pharma’s
Manufacturing Operation in Totowa, N.J.
December 20, 2005
Discovery
Labs Announces Completion of $20.0 Million in Registered
Direct Offering
December 14, 2005
Discovery Labs
to Raise $20.0 Million in Registered Direct Offering
December 11, 2005
Discovery Labs
Forms a Strategic Alliance with Chrysalis Technologies
to Develop Aerosolized SRT for Respiratory Diseases
November 29, 2005
Discovery Labs
to Present at the First Albany Capital
Conference
November 3, 2005
Discovery Labs' Reports Third Quarter Earnings and
Business Progress
November 2, 2005
Discovery Labs
to Present at the SG Cowen 6th Annual Global Health Care
Conference
November 1, 2005
Discovery Labs
Announces Conference Call and Webcast
October 28, 2005
Discovery Labs'
Surfaxin Granted Orphan Drug Designation for the
Treatment of Bronchopulmonary Dysplasia
October 21, 2005
FDA
Accepts Discovery Labs' Complete Response to Approvable
Letter for Surfaxin
October 20, 2005
Discovery Labs'
Surfaxin Licensed in Italy by Dompe Farmaceutici
October 11, 2005
Discovery Labs
Files Universal Shelf Registration Statement
September 20, 2005
Discovery Labs to Present at the UBS Global Life
Sciences Conference
September 8, 2005
Discovery
Labs Completes Pilot Phase 2 Study of Investigational
Drug Aerosurf, its Aerosolized Surfactant Delivered via
Nasal CPAP
September 1, 2005
New
Health Economic Data Shows Cost Benefit in using
Surfaxin in RDS Babies
August 19, 2005
Discovery Labs
Provides Update on Status of Response to FDA Approvable
Letter for Surfaxin
August 18, 2005
Discovery Labs
Announces Conference Call and Webcast
August 15, 2005
Discovery Labs
Provides Status of Previously Submitted Response to FDA
Approvable Letter for Surfaxin
August 9, 2005
Discovery Labs
Selected as Founding Member of the NASDAQ Health Care
Index
August 2, 2005
Discovery Labs
Reports Second Quarter 2005 Financial Results and
Business Progress
July 29, 2005
Discovery Labs Submits Response to FDA Approvable Letter
for Surfaxin for RDS in Premature Infants
July 26, 2005
Discovery Labs Announces Second Quarter Conference Call
and Webcast
May 26, 2005
Discovery
Labs to Present at the Pacific Growth 2005 Life Sciences Conference
May 18, 2005
Discovery
Labs to Present at the Needham & Company Fourth Annual
Biotechnology Conference
May 18, 2005
New Data Shows Surfaxin Survival Benefit Continues
Through One Year of Life
April 27, 2005
Discovery
Labs Reports First Quarter 2005 Financial Results and
Business Progress
April 22, 2005
Discovery
Labs Announces First Quarter Conference Call and Webcast
April 4, 2005
Discovery
Labs’ Surfaxin (lucinactant) Phase 3 Results Published
in Pediatrics, the Official Journal of the American
Academy of Pediatrics
March 15, 2005
Discovery
Labs Reports Fourth Quarter 2004 Financial Results and
Business Progress
March 10, 2005
Discovery
Labs Announces Fourth Quarter Conference Call and
Webcast
March 9, 2005
Discovery
Labs to Present at the SG Cowen 25th Annual Health Care
Conference
February
25, 2005
Discovery
Labs Announces Completion of $29.1 Million Registered
Direct Offering
February
21, 2005
Discovery
Labs to Present at the Bio CEO & Investor Conference
February
18, 2005
Discovery Labs
to Raise Additional $2.6 Million in Registered Direct Offering
February
18, 2005
Discovery Labs
to Raise $26.5 Million in Registered Direct Offering
February
14, 2005
Discovery Labs Receives Approvable Letter from FDA for
Surfaxin® for
Respiratory Distress Syndrome in Premature Infants
February
1, 2005
Discovery Labs
Provides Update on FDA Pre-Approval Inspection
Activities Pertaining to Surfaxin® NDA Status
January
31, 2005
Discovery Labs Announces Conference Call to Provide an
Update on FDA Review of Surfaxin® NDA
January 28, 2005
Discovery Labs
to Present at the Brean Murray & Co. Annual
Institutional Investor Conference
January 6, 2005
Discovery Labs Initiates Two Phase 2 Clinical Trials -
Surfaxin® for Bronchopulmonary Dysplasia and Aerosolized
SRT to Treat Neonatal Respiratory Failures
January 4, 2005
Discovery Laboratories Announces Conference Call and Webcast
